Quinazosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H23N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 436XK6QFMR, chemically known as 4-quinazolinamine, 6,7-dimethoxy-2-(4-(2-propenyl)-1-piperazinyl)- but generally known as quinazosin, which bears US NIH Compound Identifier 27486. European Medicines Agency schedules Quinazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10203MIG. The term QUINAZOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). QUINAZOSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule quinazosin under HS 29335995 and SITC 51576. As of Q4 2014, QUINAZOSIN remains the US FDA Preferred Term for this commodity. Quinazosin bears US NLM identifiers UMLS ID C2347736 and NCI Concept Code C72924. SMILES: O(C1CC2NC(N3CCN(CC3)CC=C)NC(N)C2CC1OC)C.